

CEO DR. BOB BROOKINS PRESENTS INVESTOR WEBCAST NEXT WEEK

Perth, Australia, and Greer, South Carolina- 7 September 2018- Alexium International Group Limited ("Alexium," "the Company," ASX: AJX, NASDAQ Designation: AXXIY) is pleased to announce that Chief Executive Officer Dr. Bob Brookins will present a webcast available via the Company's website on Thursday, September 13 at 10 a.m. (AEST). During the webcast, Brookins will discuss the recent Preliminary Final Report/Appendix 4E and review Alexium's progress towards its cornerstone initiatives.

Investors are welcomed to submit questions ahead of the webcast by emailing info@alexiuminternational.com between now and 5 p.m. (AEST) on Tuesday, September 11.

Current Alexium e-newsletter subscribers will receive a reminder via email on Thursday morning with instructions for accessing the on-demand webcast via the Company's website. To receive regular Alexium e-newsletters and communications, please visit the website and sign up using the form located near the bottom of the home page.

Alexium International Group Limited (ASX: AJX, Nasdaq Designation: AXXIY) holds proprietary patent applications for novel technologies developed to provide flame retardancy for a wide range of materials. These environmentally friendly flame retardants have applications for several industries and can be customized. Further, Alexium has developed products for a range of other applications including phase-change materials, water repellents, antimicrobials, and combinations thereof. Alexium also holds patents for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nanoparticles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and antimicrobial treatments. Applications under development include but are not limited to textiles, packaging, electronics, and building materials. Alexium's chemical treatments are currently marketed as Alexicool® and Alexiflam®. For additional information about Alexium, please visit www.alexiuminternational.com.

-END-

U.S. Contacts	U.S. Corporate Office	Listing Information
Mark Wise, VP Investor Relations mwise@alexiuminternational.com	350 W. Phillips Rd. Greer, SC 29650 USA US: 1.864.254.9923	ABN: 91 064 820 408 ASX: AJX Nasdaq Designation: AXXIY